BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ricardi U, Badellino S, Filippi AR. Stereotactic body radiotherapy for early stage lung cancer: History and updated role. Lung Cancer 2015;90:388-96. [DOI: 10.1016/j.lungcan.2015.10.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Wang R, Yi J, Gao H, Wei X, Shao L, Wang M, Xu W, Yin X, Shen Y, Wang Z, Wei W, Jin S, Wang B. GATA3 Exerts Distinct Transcriptional Functions to Regulate Radiation Resistance in A549 and H1299 Cells. Oxidative Medicine and Cellular Longevity 2022;2022:1-13. [DOI: 10.1155/2022/9174111] [Reference Citation Analysis]
2 Khalifa J, Lerouge D, Le Péchoux C, Pourel N, Darréon J, Mornex F, Giraud P. Radiotherapy for primary lung cancer. Cancer Radiother 2021:S1278-3218(21)00294-8. [PMID: 34953709 DOI: 10.1016/j.canrad.2021.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Li H, Zhao S, Chen X, Feng G, Chen Z, Fan S. MiR-145 modulates the radiosensitivity of non-small cell lung cancer cells by suppression of TMOD3. Carcinogenesis 2021:bgab121. [PMID: 34888652 DOI: 10.1093/carcin/bgab121] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Steinfort DP, Rangamuwa K. A glimpse of the future?-bronchoscopic ablation of peripheral early stage lung cancer. Transl Lung Cancer Res 2021;10:3861-4. [PMID: 34858776 DOI: 10.21037/tlcr-21-763] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Sato M, Yang SM, Tian D, Jun N, Lee JM. Managing screening-detected subsolid nodules-the Asian perspective. Transl Lung Cancer Res 2021;10:2323-34. [PMID: 34164280 DOI: 10.21037/tlcr-20-243] [Reference Citation Analysis]
6 Tetta C, Carpenzano M, Algargoush ATJ, Algargoosh M, Londero F, Maessen JG, Gelsomino S. Non-surgical Treatments for Lung Metastases in Patients with Soft Tissue Sarcoma: Stereotactic Body Radiation Therapy (SBRT) and Radiofrequency Ablation (RFA). Curr Med Imaging 2021;17:261-75. [PMID: 32819261 DOI: 10.2174/1573405616999200819165709] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
7 Perna M, Scotti V, Ciammella P, Borghetti P, D'angelo E, Levra NG, Fozza A, Mariotti M, Salvestrini V, Bertolini F, Vagge S, Taraborrelli M, Falcinelli L, Taddeo A, Rossi R, Costantino G, Frassinelli L, Filippi AR, Greco C, Franceschini D, Genovesi D, Lohr F, Magrini SM, Alongi F, Livi L, Bruni A. The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clin Lung Cancer 2021:S1525-7304(21)00028-0. [PMID: 33766477 DOI: 10.1016/j.cllc.2021.02.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Li Y, Sun C, Tan Y, Zhang H, Li Y, Zou H. ITGB1 enhances the Radioresistance of human Non-small Cell Lung Cancer Cells by modulating the DNA damage response and YAP1-induced Epithelial-mesenchymal Transition. Int J Biol Sci 2021;17:635-50. [PMID: 33613118 DOI: 10.7150/ijbs.52319] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wood A, Aynsley E, Kumar G, Masinghe S, Anderson M, Veeratterapillay J, Huntley C, Blower A, Green J, Johnson D, Daniel J, Curtis H, Reynolds J, Turnbull M, Harland K, Swingler A, Banham E, Burke K, Bradley J, Greenhalgh A, Peedell C. Long-term Overall Survival Outcomes in Patients with Early Stage, Peripherally Located, Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy in a Non-academic Cancer Centre. Clin Oncol (R Coll Radiol) 2021;33:283-91. [PMID: 33341333 DOI: 10.1016/j.clon.2020.12.001] [Reference Citation Analysis]
10 Kowalchuk RO, Waters MR, Baliga S, Richardson KM, Spencer KM, Larner JM, Kersh CR. Stereotactic body radiation therapy for empirically treated hypermetabolic lung lesions: a single-institutional experience identifying the Charlson score as a key prognostic factor. Transl Lung Cancer Res 2020;9:1862-72. [PMID: 33209608 DOI: 10.21037/tlcr-20-469] [Reference Citation Analysis]
11 Koizumi T, Aoki T, Saito M, Yamato Y, Furuyashiki G, Kitahara A, Hashimoto T, Watanabe T, Tsuchida M. Salvage surgery to treat tumor regrowth after stereotactic body radiotherapy in primary non-small cell lung cancer. J Thorac Dis 2020;12:5289-98. [PMID: 33209363 DOI: 10.21037/jtd-20-2253] [Reference Citation Analysis]
12 Claude L, Morelle M, Mahé MA, Pasquier D, Boisselier P, Bondiau PY, Touboul E, Peignaux-Casasnovas K, Martel-Lafay I, Gassa F, Perrier L, Dussart S, Beckendorf V. A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study. Br J Radiol 2020;93:20200256. [PMID: 32970478 DOI: 10.1259/bjr.20200256] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Jiao Y, Ren Y, Ge W, Zhang L, Zheng X. Adoption of Biologically Effective Dose of the Non-Target Lung Volume to Predict Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy With Variable Fractionations for Lung Cancer. Front Oncol 2020;10:1153. [PMID: 32850328 DOI: 10.3389/fonc.2020.01153] [Reference Citation Analysis]
14 Qiu H, Zhang L, Yi T, Yang K, Gong Y, Xie C. Retracted: Long non-coding RNA TP73-AS1 facilitates progression and radioresistance in lung cancer cells by the miR-216a-5p/CUL4B axis with exosome involvement. Thorac Cancer 2021;12:409. [PMID: 32841514 DOI: 10.1111/1759-7714.13602] [Reference Citation Analysis]
15 Rasing MJA, Peters M, Moreno AC, Hofman EFN, Herder GJM, Welvaart PWN, Schramel FMNH, Lodeweges JE, Lin SH, Verhoeff JJC, van Rossum PSN. Predicting Incomplete Resection in Non-Small Cell Lung Cancer Preoperatively: A Validated Nomogram. Ann Thorac Surg 2021;111:1052-8. [PMID: 32739254 DOI: 10.1016/j.athoracsur.2020.05.165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
16 El-Mahdy MA, Alzarie YA, Hemann C, Badary OA, Nofal S, Zweier JL. The novel SOD mimetic GC4419 increases cancer cell killing with sensitization to ionizing radiation while protecting normal cells. Free Radic Biol Med 2020;160:630-42. [PMID: 32739595 DOI: 10.1016/j.freeradbiomed.2020.07.032] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Steinfort DP, Herth FJF. Bronchoscopic treatments for early-stage peripheral lung cancer: Are we ready for prime time? Respirology 2020;25:944-52. [PMID: 32643221 DOI: 10.1111/resp.13903] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
18 Deodato F, Ferro M, Cilla S, Ianiro A, Buwenge M, Re A, Sallustio G, Valentini V, Morganti AG, Macchia G. Stereobody radiotherapy for nodal recurrences in oligometastatic patients: a pooled analysis from two phase I clinical trials. Clin Exp Metastasis 2020;37:519-29. [PMID: 32495238 DOI: 10.1007/s10585-020-10039-x] [Reference Citation Analysis]
19 Stowe H, Ogake S, Sharma S, Kelly S, McDonald M, Stanley K, Walker P, Arastu H, Granadillo CA, Bowling M, Ju A. Improved respiratory motion tracking through a novel fiducial marker placement guidance system during electromagnetic navigational bronchoscopy (ENB). Radiat Oncol 2019;14:124. [PMID: 31296231 DOI: 10.1186/s13014-019-1306-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
20 Sun C, Li Y, Tan Y, Zhang H, Liang Y, Zeng J, Yu J, Zou H. A novel role for NFIA in restoring radiosensitivity in radioresistant NSCLC cells by downregulating the AKT and ERK pathways. Biochem Biophys Res Commun 2019;515:558-64. [PMID: 31178144 DOI: 10.1016/j.bbrc.2019.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
21 Steiner E, Shieh C, Caillet V, Booth J, O'brien R, Briggs A, Hardcastle N, Jayamanne D, Szymura K, Eade T, Keall P. Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy. Radiotherapy and Oncology 2019;135:65-73. [DOI: 10.1016/j.radonc.2019.02.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
22 Hsia DW, Musani AI. Bronchoscopic Therapies for Peripheral Lung Malignancies. Clin Chest Med 2018;39:245-59. [PMID: 29433720 DOI: 10.1016/j.ccm.2017.11.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Deodato F, Macchia G, Cilla S, Ianiro A, Sallustio G, Cammelli S, Buwenge M, Mattiucci GC, Valentini V, Morganti AG. Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial. Br J Radiol 2019;92:20180422. [PMID: 30325662 DOI: 10.1259/bjr.20180422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Morias S, Marcu LG, Short M, Giles E, Potter A, Shepherd J, Gierlach T, Bezak E. Treatment-Related Adverse Effects in Lung Cancer Patients after Stereotactic Ablative Radiation Therapy. J Oncol 2018;2018:6483626. [PMID: 30402100 DOI: 10.1155/2018/6483626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
25 Morias S, Marcu LG, Short M, Giles E, Bezak E. Do SABR-related toxicities for lung cancer depend on treatment delivery? Crit Rev Oncol Hematol 2018;129:67-78. [PMID: 30097239 DOI: 10.1016/j.critrevonc.2018.06.014] [Reference Citation Analysis]
26 Benveniste MF, Gomez D, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, Marom EM. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. J Thorac Imaging 2017;32:288-99. [PMID: 28832415 DOI: 10.1097/RTI.0000000000000293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
27 Wolff HB, Alberts L, Kastelijn EA, Lissenberg-witte BI, Twisk JW, Lagerwaard FJ, Senan S, El Sharouni SY, Schramel FM, Coupé VM. Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non–Small Cell Lung Cancer. Journal of Thoracic Oncology 2018;13:689-98. [DOI: 10.1016/j.jtho.2018.01.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
28 Chia B, Landau D, Hanna G, Conibear J. Thoracic intervention and surgery to cure lung cancer: an overview of stereotactic ablative radiotherapy in early and oligometastatic lung cancer. J R Soc Med 2019;112:334-40. [PMID: 29672204 DOI: 10.1177/0141076818763334] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Benveniste MF, Welsh J, Viswanathan C, Shroff GS, Betancourt Cuellar SL, Carter BW, Marom EM. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. Radiol Clin North Am 2018;56:471-83. [PMID: 29622079 DOI: 10.1016/j.rcl.2018.01.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
30 Benveniste MF, Betancourt Cuellar SL, Gomez D, Shroff GS, Carter BW, Benveniste APA, Marom EM. Imaging of Radiation Treatment of Lung Cancer. Semin Ultrasound CT MR 2018;39:297-307. [PMID: 29807640 DOI: 10.1053/j.sult.2018.02.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
31 Weder W, Moghanaki D, Stiles B, Siva S, Rocco G. The great debate flashes: surgery versus stereotactic body radiotherapy as the primary treatment of early-stage lung cancer. European Journal of Cardio-Thoracic Surgery 2018;53:295-305. [DOI: 10.1093/ejcts/ezx410] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
32 Tu CY, Hsia TC, Fang HY, Liang JA, Yang ST, Li CC, Chien CR. A Population-based Study of the Effectiveness of Stereotactic Ablative Radiotherapy Versus Conventional Fractionated Radiotherapy for Clinical Stage I Non-small Cell Lung Cancer Patients. Radiol Oncol 2018;52:181-8. [PMID: 30018522 DOI: 10.1515/raon-2017-0058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Ma Y, Wallace AN, Waqar SN, Morgensztern D, Madaelil TP, Tomasian A, Jennings JW. Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer. Cardiovasc Intervent Radiol 2018;41:726-33. [PMID: 29204695 DOI: 10.1007/s00270-017-1843-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
34 Hörner-rieber J, Bernhardt D, Dern J, König L, Adeberg S, Paul A, Heussel CP, Kappes J, Hoffmann H, Herth FJ, Debus J, Warth A, Rieken S. Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. Radiotherapy and Oncology 2017;125:317-24. [DOI: 10.1016/j.radonc.2017.08.029] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
35 Yang J, Gao F, Xu X, Wang Y, Zhu S. Targeting protein for Xenopus kinesin-like protein 2 knockdown enhances radiation sensitivity of human lung squamous carcinoma cell. Clin Exp Pharmacol Physiol 2017;44:1060-8. [PMID: 28636807 DOI: 10.1111/1440-1681.12800] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
36 Vachani A, Sequist LV, Spira A. AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. Am J Respir Crit Care Med 2017;195:1150-60. [PMID: 28459327 DOI: 10.1164/rccm.201702-0433CI] [Cited by in Crossref: 44] [Cited by in F6Publishing: 57] [Article Influence: 8.8] [Reference Citation Analysis]
37 Sun Y, Duan Q, Chen X, Chen W, Jin X, Wu R. Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma. Clin Transl Oncol 2017;19:1498-506. [PMID: 28589432 DOI: 10.1007/s12094-017-1694-2] [Reference Citation Analysis]
38 Desai NB, Laine AM, Timmerman RD. Stereotactic ablative body radiotherapy (SAbR) for oligometastatic cancer.Br J Radiol. 2017;90:20160500. [PMID: 28008774 DOI: 10.1259/bjr.20160500] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
39 Rieber J, Abbassi-Senger N, Adebahr S, Andratschke N, Blanck O, Duma M, Eble MJ, Ernst I, Flentje M, Gerum S, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lohaus F, Lohr F, Petersen C, Schrade E, Streblow J, Uhlmann L, Wittig A, Sterzing F, Guckenberger M. Influence of Institutional Experience and Technological Advances on Outcome of Stereotactic Body Radiation Therapy for Oligometastatic Lung Disease. Int J Radiat Oncol Biol Phys. 2017;98:511-520. [PMID: 27843031 DOI: 10.1016/j.ijrobp.2016.09.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
40 Sepesi B, Rice DC, Heymach JV, Vaporciyan AA, Swisher SG. Stage I lung cancer-to operate or to radiate? that is the question. J Thorac Dis 2016;8:2324-7. [PMID: 27746966 DOI: 10.21037/jtd.2016.08.36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Lischalk JW, Woo SM, Kataria S, Aghdam N, Paydar I, Repka MC, Anderson ED, Collins BT. Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). J Radiat Oncol 2016;5:379-87. [PMID: 28018523 DOI: 10.1007/s13566-016-0273-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
42 Shi S, Zeng Z, Ye L, Huang Y, He J. Risk Factors Associated With Symptomatic Radiation Pneumonitis After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer. Technol Cancer Res Treat 2017;16:316-20. [PMID: 27516466 DOI: 10.1177/1533034616661665] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
43 Yao YH, Cui Y, Qiu XN, Zhang LZ, Zhang W, Li H, Yu JM. Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non-small cell lung cancer cells. Chin J Cancer 2016;35:50. [PMID: 27266881 DOI: 10.1186/s40880-016-0113-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 4.5] [Reference Citation Analysis]